Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents

Trial Profile

Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Zotarolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Myocardial ischaemia; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms LONG-DES VI
  • Most Recent Events

    • 23 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 07 Dec 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
    • 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top